Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLFS BioLife Solutions	$22.35 +0.4%	$23.02	$18.70 ▼ $29.55	$1.06B	2.01	386,097 shs	479,470 shs
INMD InMode	$14.39 -1.0%	$15.36	$13.68 ▼ $19.85	$909.58M	2.02	1.19 million shs	730,134 shs
MDXG MiMedx Group	$6.51 -3.8%	$7.00	$5.47 ▼ $10.14	$961.54M	1.85	691,738 shs	645,993 shs
STIM Neuronetics	$3.85 -3.0%	$4.08	$0.52 ▼ $5.92	$261.31M	1.92	752,555 shs	395,955 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLFS BioLife Solutions	+0.40%	+1.18%	-8.66%	-5.22%	+0.99%
INMD InMode	-1.03%	+1.27%	+0.91%	-22.50%	-26.66%
MDXG MiMedx Group	-3.84%	-5.65%	-4.69%	-20.02%	-13.32%
STIM Neuronetics	-3.02%	-3.99%	-13.48%	-10.05%	+85.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLFS BioLife Solutions	2.4259 of 5 stars	3.5	1.0	3.3	2.5	0.6
INMD InMode	3.909 of 5 stars	4.1	3.0	3.9	1.7	1.9
MDXG MiMedx Group	3.7273 of 5 stars	3.5	2.0	4.1	3.3	1.9
STIM Neuronetics	2.8006 of 5 stars	3.3	4.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLFS BioLife Solutions	3.00	Buy	$31.17	39.45% Upside
INMD InMode	2.13	Hold	$18.54	28.85% Upside
MDXG MiMedx Group	3.00	Buy	$12.50	92.01% Upside
STIM Neuronetics	2.67	Moderate Buy	$5.50	42.86% Upside

Current Analyst Ratings Breakdown

Latest STIM, BLFS, MDXG, and INMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	BLFS BioLife Solutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/30/2025	INMD InMode	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $24.00
4/29/2025	INMD InMode	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$19.00 ➝ $16.25
4/29/2025	INMD InMode	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $15.00
4/29/2025	INMD InMode	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/28/2025	INMD InMode	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/28/2025	INMD InMode	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$22.00 ➝ $16.00
4/28/2025	INMD InMode	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/14/2025	INMD InMode	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$16.00 ➝ $15.00
4/9/2025	INMD InMode	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/6/2025	BLFS BioLife Solutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $30.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLFS BioLife Solutions	$87.76M	12.10	N/A	N/A	$7.67 per share	2.91
INMD InMode	$392.41M	2.32	$1.38 per share	10.40	$10.12 per share	1.42
MDXG MiMedx Group	$352.38M	2.73	$0.16 per share	41.75	$0.98 per share	6.64
STIM Neuronetics	$89.45M	2.83	N/A	N/A	$1.18 per share	3.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLFS BioLife Solutions	-$66.43M	-$0.29	N/A	N/A	N/A	-38.98%	-6.61%	-5.54%	8/14/2025 (Estimated)
INMD InMode	$181.27M	$2.33	6.12	7.91	N/A	45.91%	18.25%	16.33%	8/7/2025 (Estimated)
MDXG MiMedx Group	$58.23M	$0.27	11.84	20.34	N/A	23.86%	26.21%	18.15%	7/30/2025 (Estimated)
STIM Neuronetics	-$30.19M	-$1.31	N/A	N/A	N/A	-50.09%	-141.24%	-32.77%	8/11/2025 (Estimated)

Latest STIM, BLFS, MDXG, and INMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	BLFS BioLife Solutions	-$0.03	$0.04	+$0.07	-$0.01	$22.22 million	$23.94 million
5/6/2025	Q1 2025	STIM Neuronetics	-$0.13	-$0.21	-$0.08	-$0.21	$29.07 million	$31.98 million
4/30/2025	Q1 2025	MDXG MiMedx Group	$0.06	$0.06	N/A	$0.05	$86.32 million	$88.21 million
4/28/2025	Q1 2025	INMD InMode	$0.45	$0.31	-$0.14	$0.26	$82.21 million	$77.87 million
3/3/2025	Q4 2024	BLFS BioLife Solutions	-$0.06	$0.26	+$0.32	$0.26	$21.73 million	$22.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLFS BioLife Solutions	N/A	N/A	N/A	N/A	N/A
INMD InMode	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
STIM Neuronetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLFS BioLife Solutions	0.03	2.78	1.78
INMD InMode	N/A	10.23	9.38
MDXG MiMedx Group	0.10	4.10	3.53
STIM Neuronetics	4.90	3.16	2.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLFS BioLife Solutions	93.24%
INMD InMode	68.04%
MDXG MiMedx Group	79.15%
STIM Neuronetics	53.59%

Insider Ownership

Company	Insider Ownership
BLFS BioLife Solutions	2.20%
INMD InMode	6.92%
MDXG MiMedx Group	1.70%
STIM Neuronetics	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLFS BioLife Solutions	440	47.50 million	45.37 million	Optionable
INMD InMode	480	63.21 million	64.75 million	Optionable
MDXG MiMedx Group	870	147.70 million	145.04 million	Optionable
STIM Neuronetics	180	65.82 million	27.37 million	Optionable

STIM, BLFS, MDXG, and INMD Headlines

Recent News About These Companies

Neuronetics, Inc. (NASDAQ:STIM) EVP Sells $826,074.20 in Stock

May 15, 2025 | insidertrades.com

Balyasny Asset Management L.P. Grows Position in Neuronetics, Inc. (NASDAQ:STIM)

May 15, 2025 | marketbeat.com

Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

May 14, 2025 | tmcnet.com

Q2 EPS Estimates for Neuronetics Reduced by William Blair

May 11, 2025 | marketbeat.com

Neuronetics Announces Inducement Awards for New Team Members

May 10, 2025 | msn.com

Neuronetics, Inc. (NASDAQ:STIM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$6.83

May 9, 2025 | finance.yahoo.com

Neuronetics (NASDAQ:STIM) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS

May 8, 2025 | marketbeat.com

Renaissance Technologies LLC Has $255,000 Position in Neuronetics, Inc. (NASDAQ:STIM)

May 8, 2025 | marketbeat.com

Earnings call transcript: Neuronetics Q1 2025 misses EPS, stock drops 22%

May 7, 2025 | investing.com

Neuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook Acquisition

May 7, 2025 | nasdaq.com

Neuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook Acquisition

May 7, 2025 | nasdaq.com

Neuronetics Inc (STIM) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Margin Challenges

May 7, 2025 | finance.yahoo.com

Neuronetics, Inc. (STIM) Q1 2025 Earnings Call Transcript

May 6, 2025 | seekingalpha.com

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

Neuronetics Reports First Quarter 2025 Financial and Operating Results

May 6, 2025 | globenewswire.com

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 5, 2025 | globenewswire.com

Neuronetics (STIM) to Release Quarterly Earnings on Tuesday

May 1, 2025 | marketbeat.com

Why Neuronetics, Inc. (STIM) is Surging in 2025

April 30, 2025 | msn.com

Neuronetics to Announce Q1 2025 Results and Host Live Conference Call on May 6

April 24, 2025 | msn.com

Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

April 22, 2025 | tmcnet.com

Neuronetics Announces Expanded Coverage for NeuroStar TMS to Treat Adolescent Depression

April 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Workday Stock Price Implosion: An Automatic Buy for AI Investors
By Thomas Hughes | May 26, 2025
View Workday Stock Price Implosion: An Automatic Buy for AI Investors
Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan
By Jeffrey Neal Johnson | May 3, 2025
View Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan

STIM, BLFS, MDXG, and INMD Company Descriptions

BioLife Solutions NASDAQ:BLFS

$22.35 +0.09 (+0.40%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$22.82 +0.47 (+2.10%)

As of 05/28/2025 07:45 PM Eastern

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

InMode NASDAQ:INMD

$14.39 -0.15 (-1.03%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$14.61 +0.22 (+1.53%)

As of 05/28/2025 07:59 PM Eastern

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

MiMedx Group NASDAQ:MDXG

$6.51 -0.26 (-3.84%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$6.51 0.00 (0.00%)

As of 05/28/2025 07:01 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Neuronetics NASDAQ:STIM

$3.85 -0.12 (-3.02%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$3.83 -0.02 (-0.55%)

As of 05/28/2025 07:43 PM Eastern

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time